Hostname: page-component-8448b6f56d-gtxcr Total loading time: 0 Render date: 2024-04-19T01:09:13.213Z Has data issue: false hasContentIssue false
  • English
  • Français

Off-label prescribing

Published online by Cambridge University Press:  02 January 2018

Francesca Lowe-Ponsford  and
David Baldwin
Francesca Lowe-Ponsford
Affiliation:
Box 317, Adrian House, Fulbourn Hospital, Cambridge CB15EF
David Baldwin
Affiliation:
University Department of Mental Health, Royal South Hants Hospital, BrintonsTerrace, Southampton SO14 0YG
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Columns
Information
Psychiatric Bulletin , Volume 26 , Issue 10 , October 2002 , pp. 394
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2002. The Royal College of Psychiatrists

Sir: We enjoyed reading the article by Lawrence et al (Psychiatric Bulletin, June 2002, 26, 230-232). The findings complement some work that we have done in this area (Lowe-Ponsford, Psychiatric Bulletin, 2000, 24, 415-417). Our postal questionnaire found that 65% of psychiatrists who replied had prescribed ‘off-label’ within the preceding month.

Medico-legal advice that we obtained (from the Medical Protection Society) was that, not only does Bolam (1957) need to be taken into account, but also the case of Bolitho (1997). This judgement means that the treatment has to withstand logical analysis as well as be accepted by a body of opinion. These considerations need to be taken into account in prescribing, alongside the capacity of the patient.

Many psychiatrists are worried about off-label prescribing and our study showed that 4% of respondents had received complaints about this matter. In our paper, we suggested some guidelines that may avoid many future medico-legal problems for clinicians if they should prescribe off-label.

The College's Psychopharmacology Special Interest Group has discussed this matter and is setting up a small working group (chaired by D. B.) to review the practice of off-label prescribing. We would be delighted to receive the thoughts of colleagues on this subject.

References

Bolam v. Friern. Hospital Management Committee [1957] 2AllER 118, 1W:R582.Google Scholar
Bolitho v. City and Hackney Health Authority [1997] 3 WLR 1151.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.